Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1975 Oct;34(5):444–450. doi: 10.1136/ard.34.5.444

Prognostic significance of DNA-binding capacity patterns in patients with lupus nephritis.

M K Adler, A Baumgarten, B Hecht, N J Siegel
PMCID: PMC1006446  PMID: 1221925

Abstract

The time course of DNA binding capacity (DNA-bc) was found to correlate with the clinical course in a group of 21 patients who had biopsy-proven lupus glomerulonephritis and were treated with immunosuppressive agents. Eight patients showed a sequential DNA-bc pattern in which a high titre of anti-DNA antibody was present for a prolonged period of time all having an unfavourable clinical course. Persistently high values of DNA-bc preceded by as much as 10 months evidence of renal deterioration obtained by conventional renal function tests. Thirteen patients showed a low titre of anti-DNA antibody throughout most of their course, 12 having a favourable outcome. An initially high value of DNA-bc had no prognostic significance. These results suggest that the persistence of a high titre of anti-DNA antibody in patients with lupus glomerulonephritis is a poor prognostic sign.

Full text

PDF
444

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin D. S., Lowenstein J., Rothfield N. F., Gallo G., McCluskey R. T. The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med. 1970 Dec;73(6):929–942. doi: 10.7326/0003-4819-73-6-929. [DOI] [PubMed] [Google Scholar]
  2. CASALS S. P., FRIOU G. J., MYERS L. L. SIGNIFICANCE OF ANTIBODY TO DNA IN SYSTEMIC LUPUS ERYTHEMATOSUS. Arthritis Rheum. 1964 Aug;7:379–390. doi: 10.1002/art.1780070404. [DOI] [PubMed] [Google Scholar]
  3. Cochrane C. G., Koffler D. Immune complex disease in experimental animals and man. Adv Immunol. 1973;16(0):185–264. doi: 10.1016/s0065-2776(08)60298-9. [DOI] [PubMed] [Google Scholar]
  4. Epstein W. V., Grausz H. Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus. Arthritis Rheum. 1974 Mar-Apr;17(2):129–142. doi: 10.1002/art.1780170205. [DOI] [PubMed] [Google Scholar]
  5. FARR R. S. A quantitative immunochemical measure of the primary interaction between I BSA and antibody. J Infect Dis. 1958 Nov-Dec;103(3):239–262. doi: 10.1093/infdis/103.3.239. [DOI] [PubMed] [Google Scholar]
  6. Hahn B. H., Bagby M. K., Hamilton T. R., Osterland C. K. Comparison of therapeutic and immunosuppressive effects of azathioprine, prednisolone and combined therapy in NZP-NZW mice. Arthritis Rheum. 1973 Mar-Apr;16(2):163–170. doi: 10.1002/art.1780160205. [DOI] [PubMed] [Google Scholar]
  7. Harbeck R. J., Bardana E. J., Kohler P. F., Carr R. I. DNA:anti-DNA complexes: their detection in systemic lupus erythematosus sera. J Clin Invest. 1973 Apr;52(4):789–795. doi: 10.1172/JCI107242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hughes G. R., Cohen S. A., Christian C. L. Anti-DNA activity in systemic lupus erythematosus. A diagnostic and therapeutic guide. Ann Rheum Dis. 1971 May;30(3):259–264. doi: 10.1136/ard.30.3.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hughes G. R. Significance of anti-D.N.A. antibodies in systemic lupus erythematosus. Lancet. 1971 Oct 16;2(7729):861–863. doi: 10.1016/s0140-6736(71)90234-0. [DOI] [PubMed] [Google Scholar]
  10. Koffler D., Kunkel H. G. Mechanisms of renal injury in systemic lupus erythematosus. Am J Med. 1968 Aug;45(2):165–169. doi: 10.1016/0002-9343(68)90034-x. [DOI] [PubMed] [Google Scholar]
  11. Luciano A., Rothfield N. F. Patterns of nuclear fluorescence and DNA-binding activity. Ann Rheum Dis. 1973 Jul;32(4):337–341. doi: 10.1136/ard.32.4.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pincus T., Schur P. H., Rose J. A., Decker J. L., Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med. 1969 Sep 25;281(13):701–705. doi: 10.1056/NEJM196909252811304. [DOI] [PubMed] [Google Scholar]
  13. Schur P. H., Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med. 1968 Mar 7;278(10):533–538. doi: 10.1056/NEJM196803072781004. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES